Between Medical Technology and Changing Markets, Philips Navigates a More Complicated Health Landscape From Amsterdam

Healthcare technology often moves at a different pace from ordinary commerce. A medical device can take years to design, approve, purchase, and install, while a large hospital contract can shift from one quarter to another with little warning. For Philips, those long cycles shaped the picture emerging from its latest results.

The Dutch healthcare technology company reported 4% comparable sales growth in the second quarter of 2026, with group sales reaching €4.4 billion. However, comparable order intake declined 1%, partly because several large orders were delayed.

Philips said the delays involved large U.S. contracts and described them as timing issues rather than canceled business. Chief Executive Roy Jakobs noted that some contracts are very large and can take considerable time to close, meaning their contribution can shift between reporting periods.

The company nevertheless reported an adjusted EBITA margin of 16.4% for the quarter, including the benefit of a U.S. tariff refund. Philips also increased its adjusted EBITA and free-cash-flow outlook for 2026 to reflect that refund.

China presents a different challenge. Philips has faced pressure in the Chinese healthcare market following changes to the procurement environment for public medical institutions. The company said the developments had created a more difficult market situation, particularly for its Diagnosis & Treatment business.

The issue illustrates how medical technology companies operate within systems that extend far beyond laboratories and hospitals. Equipment purchases depend on government procurement structures, hospital budgets, currency movements, trade conditions, and the timing of major contracts.

For Philips, China remains an important market, but management has acknowledged that conditions there have become structurally more challenging. The company has therefore had to consider not only current sales but also how changes in procurement and market demand could influence its performance over the longer term.

At the same time, the underlying sales performance remained relatively resilient. Philips said comparable sales growth was driven across all business segments, while operating income reached €609 million, including the €186 million benefit from the U.S. tariff refund.

The contrast between sales growth and weaker order intake gives the quarter an unusual shape. Existing business continued to generate revenue, while the timing of new large contracts created uncertainty about future quarters. That distinction is important in an industry where individual orders can be substantial and spread across several years.

Philips therefore enters the remainder of 2026 with its full-year comparable sales growth outlook reiterated, while its profitability and cash-flow expectations have been adjusted for the U.S. tariff refund. The company continues to navigate delayed contracts and a more difficult Chinese market while maintaining investment in healthcare technology.

AI Image Disclaimer The images accompanying this article are AI-generated conceptual visuals and should not be interpreted as real photographs of Philips facilities, medical equipment, or reported events.

Sources Reuters Philips Investing.com NL Times The Wall Street Journal